Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性

doi:10.11904/j.issn.1002-3070.2019.02.005

Abstract

Abstract: Objective The aim of this study was to investigate the expression of cell cycle checkpoint kinase 1(Chk1)gene in glioblastoma cells(GBM)and its correlation with GBM cell proliferation,tumorigenic activity and prognosis. Methods The expression of Chk1 in GBM cells was selected and analyzed by TCGA database and brain tumor molecular database(Rembrandt),and the level of Chk1 expression in GBM cells was detected by molecular biology techniques such as Western blot and Real-Time PCR.The expression of Chk1 was silenced by siRNA to investigate its effect on proliferation and colony-forming ability of GBM cells.The prognosis survival of GBM patients accompanying with Chk1 expression was analyzed by immunohistochemical staining and Rembrandt database. Results The results of TCGA database and Rembrandt showed that Chk1 gene was highly expressed in GBM tissues.Western blot and Real-Time PCR also showed that Chk1 gene was highly expressed in GBM cells.Lentiviral transfection siRNA-specific silencing of Chk1 significantly inhibited proliferation and colony-forming ability of U87 cells(P＜0.01 and P＜0.05).Prognostic survival analysis showed that GBM patients with low expression of Chk1 gene had a significantly better clinical outcome than those of GBM patients with high expression of Chk1 gene(P＜0.001). Conclusion Chk1 gene is overexpressed in GBM cells,up-regulation of Chk1 gene expression can promote the growth and proliferation of GBM cells,and Chk1 gene is associated with poor prognosis in GBM patients.

Key words: Glioblastoma, Chk1, Cell proliferation, Prognosis

CLC Number:

BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.

References

1 Qi L,Ding L,Wang S,et al.A network meta-analysis:the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy(RT)[J].Oncotarget,2016,7(42):69002-69013.
2 Signorovitch J,Li N,Ohashi E,et al.Overall survival(Os),quality of life(Qol),and Neurocognitive function(Nf)in recurrent glioblastoma multiforme(Gbm):a systematic literature review[J].Value Health,2015,18(7):433.
3 Furusawa Y,Yamanouchi Y,Iizumi T,et al.Checkpoint kinase 2 is dispensable for regulation of the p53 response but is required for G2/M arrest and cell survival in cells with p53 defects under heat stress[J].Apoptosis,2017,22(10):1225-1234.
4 Gali-Muhtasib H,Kuester D,Mawrin C,et al.Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells[J].Cancer Res,2008,68(14):5609-56018.
5 Alcaraz-Sanabria A,Nieto-Jimenez C,Corrales-Sanchez V,et al.Synthetic lethality interaction between Aurora kinases and CHEK1 inhibitors in ovarian cancer[J].Mol Cancer Ther,2017,16(11):2552-2562.
6 Liu B,Qu J,Xu F,et al.MiR-195 suppresses non-small cell lung cancer by targeting CHEK1[J].Oncotarget,2015,6(11):9445-9456.
7 Lin WY,Brock IW,Connley D,et al.Associations of ATR and CHEK1 single nucleotide polymorphisms with breast cancer[J].PLoS One,2013,8(7):e68578.
8 Kim MK,Min DJ,Wright G,et al.Loss of compensatory pro-survival and anti-apoptotic modulator,IKKepsilon,sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21[J].Oncotarget,2014,5(24):12788-12802.
9 Kim MK,James J,Annunziata CM.Topotecan synergizes with CHEK1(CHK1)inhibitor to induce apoptosis in ovarian cancer cells[J].BMC Cancer,2015,15:196.
10 Bai X,Wang J,Huo L,et al.Serine/Threonine kinase CHEK1-dependent transcriptional regulation of RAD54L promotes proliferation and radio resistance in glioblastoma[J].Transl Oncol,2018,11(1):140-146.
11 Wang J,Cheng P,Pavlyukov MS,et al.Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2[J].J Clin Invest,2017,127(8):3075-3089.
12 Teo M,Martin S,Owusu-Agyemang K,et al.A survival analysis of GBM patients in the West of Scotland pre-and post-introduction of the Stupp regime[J].Br J Neurosurg,2014,28(3):351-355.
13 Duffau H.Glioblastoma in 2017[J].Rev Infirm,2017,66(228):16-18.
14 Sun X,Xiao D,Xu T,et al.miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5[J].Future Oncol,2016,12(23):2701-2712.
15 Abdel-Fatah TM,Middleton FK,Arora A,et al.Untangling the ATR-CHEK1 network for prognostication,prediction and therapeutic target validation in breast cancer[J].Mol Oncol,2015,9(3):569-585.
16 Matsumoto K,Nagahara T,Okano J,et al.The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases[J].Oncol Rep,2008,20(4):863-872.
17 Zuco V,Benedetti V,De Cesare M,et al.Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor,RC307:enhanced DNA damage response[J].Int J Cancer,2010,126(5):1246-1255.
18 Sankunny M,Parikh RA,Lewis DW,et al.Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss[J].Genes Chromosomes Cancer,2014,53(2):129-143.
19 Lam MH,Rosen JM.Chk1 versus Cdc25:chking one's levels of cellular proliferation[J].Cell Cycle,2004,3(11):1355-1357.
20 Kohn EA,Ruth ND,Brown MK,et al.Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation[J].J Biol Chem,2002,277(29):26553-26564.
21 Levesque AA,Fanous AA,Poh A,et al.Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest[J].Mol Cancer Ther,2008,7(2):252-262.

[1]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[2]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[3]	SHI Xiaokang, DING Youming, WANG Bin, YU Bin, XU Yu. Expression and clinical significance of UBE2T in primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 128-133.
[4]	LU Jiaoyun, ZHANG Qingyuan. Advances in laboratory markers in the prognosis of diffuse large B-cell lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 183-187.
[5]	YUAN Guixia, LI Yan, FENG Wanqi, XIA Xiaojuan, LI Xu. Mechanism of tumor suppressor gene DKK2 inhibiting proliferation of nephroblastoma cells in children [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 14-20.
[6]	ZHAO Fengjuan, WANG Qi, REN Yunhong, WEI Jueling, LI Lequn, ZHAO Xinhua, TANG Juan, YOU Xuemei. Changes of serum CRP and hs-CRP levels in patients with liver cancer and depression and their influence on prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 27-33.
[7]	ZHANG Fengchun, JIANG Ying, LIU Zhaonan, YAN Ningning, CUI Hongquan, XU Yingchun. Prognostic significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in systemic inflammation-related indicators in gastric cancer patients after radical resection [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 34-39.
[8]	MA Jianli, ZHANG Minghui, JI Hongfei, XU Xiangying. Clinical significance of combined detection of PD-L1 protein and CD8⁺TILs in resected lung adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 40-46.
[9]	YANG Hongbo, SHI Jie, YE Yong, LI Wencheng, DENG Zhaoping. Expression of COL5A2 in bladder cancer tissues and its correlation with clinicopathological features and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 52-56.
[10]	WANG Yalong, LYU Zhangyan, ZHANG Fan, FENG Xiaoshuang, WEI Luopei, LI Xin, WEN Yan, GAO Yushun, XUE Qi, GAO Shugeng, TAN Fengwei. Relationship between human papillomavirus infection and prognosis of lung cancer:A meta-analysis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 520-526.
[11]	TANG Shuli, HE Kuangbang, ZHANG Chunhui, CHENG Jianan, ZHANG Yanqiao. Expression of miR-320a and CYLD in gastric cancer and its relationship with clinicopathological characteristics and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 538-544.
[12]	XIAO Hongwei, CHEN Sheng, WANG Yanliang, SU Xueliang. The prognostic and influence factors analysis of transanal local resection for stage T₁ rectal cancer with the distance from anal margin ≤8 cm [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 545-549.
[13]	LIU Juan, ZHANG Shutian. Advances in research on the mechanism of cyclin-dependent kinase inhibitor 3(CDKN3)in tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 575-578.
[14]	WANG Yiran, HUANG Wei, YIN Lei, LIU Lin, ZHOU Xiaoping, NIU Xingjian, YANG Yue, AN Weiwei, JI Hongfei. The ratio of neutrophil to lymphocyte in the efficacy and prognosis of concurrent chemoradiotherapy in patients with cervical cancer and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 404-409.
[15]	LI Meiyan, CHEN Yongxue, HOU Junde. Effects of Leptin,VEGF and different anesthesia methods on prognosis of endometrial cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 426-431.

Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments